Pay for Delay
A first-generation tactic where a brand company pays the first-filing generic to stay off the market, sharing monopoly rent to prolong high prices.
As defined in Robin Feldman on Drug Patents, Generics, and Drug Wars
Where it comes up · 1
Most important claims · 4 of 4Search all claims for “Pay for Delay” →
- Because the statute prevents any other generic from entering until the first-filing generic has actually come to market, a brand company can pay that first generic to stay off the market and thereby block all subsequent generic competition, since the six-month exclusivity clock never starts running.Robin Feldman on Drug Patents, Generics, and Drug Wars
- In the first-generation Pay-for-Delay strategy, a brand-name company settles a Hatch-Waxman lawsuit by paying the first-filing generic to stay off the market for a period—effectively sharing part of its monopoly rent with the generic so both profit while consumers and society lose through prolonged high prices.Robin Feldman on Drug Patents, Generics, and Drug Wars
- The defense of pay-for-delay as a rational settlement is suspect because in ordinary settlements the defendant pays the plaintiff, not the reverse; here the plaintiff (brand) paying the defendant (generic) strongly suggests the deal is not about resolving litigation risk but about protecting and extending an exclusivity the company is not supposed to have.Robin Feldman on Drug Patents, Generics, and Drug Wars
- The Supreme Court's 2013 Actavis decision ruled that pay-for-delay settlements could be challenged as antitrust violations; though limited, that pronouncement let lower courts attack these deals and, in anticipation, companies began moving away from simple pay-for-delay settlements.Robin Feldman on Drug Patents, Generics, and Drug Wars